B38.2 Pulmonary coccidioidomycosis, unspecified

Name of the Condition

• Pulmonary coccidioidomycosis, unspecified

Summary

Pulmonary coccidioidomycosis, unspecified, is a fungal infection of the lungs caused by Coccidioides species. It represents a form of coccidioidomycosis where the pulmonary involvement is not further specified as acute or chronic. The condition may range from asymptomatic or mild respiratory symptoms to more severe disease, particularly in individuals with weakened immune systems. The unspecified designation indicates that the clinical details of the pulmonary presentation are not documented with greater specificity.

Causes

The infection results from inhaling airborne spores of Coccidioides fungi, which are endemic to arid regions such as the southwestern United States, Mexico, and parts of Central and South America. These spores are released from soil and can become airborne during activities that disturb the ground, including construction, farming, or windstorms. Inhalation of the spores leads to infection, with the lungs being the primary site of involvement.

Risk Factors

• Residence or travel to endemic regions, especially during dry, dusty seasons.
• Occupational exposure to soil (e.g., farmers, construction workers, archaeologists).
• Immunocompromised states, including HIV/AIDS, organ transplantation, or prolonged corticosteroid use.
• Pregnancy, particularly the third trimester.
• Advanced age.

Symptoms

• Fatigue and malaise.
• Cough, chest pain, or shortness of breath.
• Fever, night sweats, or weight loss.
• Joint pain or skin rash (erythema nodosum).
• Severe cases may involve progressive respiratory decline or dissemination to other organs.

Diagnosis

Diagnosis involves clinical evaluation, imaging (e.g., chest X-ray or CT scan), and laboratory testing. Imaging may show pulmonary infiltrates, nodules, or cavities. Laboratory confirmation typically includes serologic tests (e.g., coccidioides antibody detection) or fungal culture from respiratory specimens. Histopathologic examination of tissue samples may also be used to identify the organism.

Treatment Options

Treatment depends on the severity of the infection and the patient’s immune status. Mild cases may resolve without specific antifungal therapy. Moderate to severe disease, or infections in immunocompromised individuals, often require antifungal medications such as fluconazole, itraconazole, or amphotericin B. Duration of therapy varies based on clinical response and immune status.

Prognosis and Follow-Up

Prognosis is generally favorable for immunocompetent individuals with mild disease, with many cases resolving spontaneously. However, severe or disseminated infections, particularly in immunocompromised patients, can be life-threatening. Follow-up may include monitoring for symptom resolution, repeat imaging, or serologic testing to assess treatment response. Long-term surveillance may be necessary for those with chronic or complicated disease.

Complications

• Progressive respiratory failure.
• Dissemination to other organs (e.g., skin, bones, central nervous system).
• Chronic pulmonary coccidioidomycosis, including cavitation or fibrosis.
• Meningitis or other central nervous system involvement in severe cases.

Lifestyle & Prevention

• Avoiding activities that disturb soil in endemic areas, such as construction or farming, during high-risk seasons.
• Using respiratory protection (e.g., masks) when exposure to dust is unavoidable.
• Staying informed about local endemic regions and taking precautions during travel.
• Maintaining overall health to support immune function.

When to Seek Professional Help

Seek medical attention if symptoms such as persistent cough, chest pain, fever, or unexplained weight loss develop, especially after potential exposure to endemic areas. Prompt evaluation is critical for individuals with weakened immune systems, as they are at higher risk for severe disease.

Tips for Medical Coders

When coding for pulmonary coccidioidomycosis, unspecified (B38.2), ensure documentation supports the lack of further specification regarding the pulmonary presentation (e.g., acute vs. chronic). Verify that the diagnosis aligns with clinical findings and that no more specific pulmonary coccidioidomycosis code (e.g., acute or chronic) is applicable. Document the absence of additional details to justify the unspecified designation.